Lyell Immunopharma (LYEL) Fundamental Analysis: Revenue, Earnings & Valuation

3.62 / 10

Netural

Fundamental analysis rates LYEL at 3.6/10, indicating subpar quality. PB‑ROE and cash‑to‑market are modestly positive, while Asset‑MV and fixed‑asset turnover are weak. Revenue YoY plummets –41%, though inventory turnover is strong and gross margin hits 100%. Overall, fundamentals are challenging.

Analysis Checks(7/10)

Revenue-MV

Value-11.95

Score2/3

Weight18.42%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value-40.98

Score3/3

Weight2.93%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.02%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.42%

1M Return1.69%

PB-ROE

Value25.66

Score2/3

Weight14.21%

1M Return6.97%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.87%

1M Return-0.50%

Fixed assets turnover ratio

Value0.00

Score1/3

Weight-2.09%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.69%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight26.94%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight13.34%

1M Return5.94%

Is LYEL fundamentally strong?

LYEL scores 3.62/10 on fundamentals and holds a Fair valuation at present. Backed by its -86.98% ROE, -762355.56% net margin, -1.77 P/E ratio, 1.95 P/B ratio, and 38.77% earnings growth, these metrics solidify its Netural investment rating.